Logo

GTG Settles Patent Infringement Litigation with RGI

Jul 03, 2013 | staff reporter

NEW YORK (GenomeWeb News) – Genetic Technologies said late last week that it has settled with Reproductive Genetics Institute over allegations that RGI infringed GTG's patent covering its non-coding DNA technology.

Terms of the settlement were not disclosed.

GTG sued RGI last August alleging Chicago-based RGI infringed US Patent No. 5,612,179 titled "Intron Sequence Analysis Method for Adjacent Locus Alleles as Haplotypes," with its screening services for cystic fibrosis. GTG, based in Melbourne, Australia, had asked the US District Court for the Northern District of Illinois Eastern Division for unspecified damages.

Last week, GTG announced a deal to settle patent infringement allegations it leveled against Bioscientia Institute.

Filed under

Diagnostics
Business News
Tools & Technology
intellectual property
non-coding DNA
Genetic Technologies
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.